Rovalpituzumab Tesirine Biosimilar Antibody-Drug Conjugate (DLL3) for Research
Pre-made Rovalpituzumab Tesirine benchmark antibody (Whole mAb ADC, anti-DLL3 therapeutic antibody, Anti-SCDO1 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Rovalpituzumab tesirine (Rova-T) is an experimental antibody-drug conjugate targeting the protein DLL3 on tumor cells.[1][2] It was originally developed by Stemcentrx and was purchased by AbbVie.[3] It was tested for use in small-cell lung cancer, but development was terminated after unsuccessful phase III trial.[4][5]
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-980-1mg | 1mg | |
| GMP-Bios-INN-980-10mg | 10mg | |
| GMP-Bios-INN-980-100mg | 100mg | |
| GMP-Bios-INN-980-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Rovalpituzumab Tesirine Biosimilar, Whole Mab Adc, Anti-Dll3 Antibody: Anti-SCDO1 therapeutic antibody Drug Conjugate |
| INN Name | Rovalpituzumab Tesirine |
| Target | DLL3 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Stemcentrx, Inc. (San Francisco CA USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - DLL3
1. Protein Delta-like protein 3
2. Gene DLL3
3. Organism Homo sapiens (Human)
Function
Inhibits primary neurogenesis. May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm (By similarity).

